NCT05638360

Brief Summary

The purpose of this study is to assess the efficacy and safety of Ru-Yi-Jin-Huang-Saan for the treatment of Colles' fracture.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 6, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

May 1, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

March 19, 2025

Status Verified

August 1, 2024

Enrollment Period

2.2 years

First QC Date

November 26, 2022

Last Update Submit

March 16, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline in Patient-Rated Wrist Evaluation(PRWE) scale at Day 6

    The PRWE scale is a 15-item questionnaire designed to measure wrist pain and disability in activities of daily living. 1. Pain subscale: contains 5 items each of which is further rated from 1-10. The maximum score in this section is 50 and minimum 0. 2. Function subscale: contains total 10 items which are further divided into 2 sections i.e specific activities (having 6 items) and usual activities (having 4 items). The maximum score in this section is 50 and minimum 0. Possible scores range from 0 (best score) to 100 (worst score). Change = (Day 6 score - Baseline score)

    Baseline and Day 6

Secondary Outcomes (2)

  • Change from Baseline in C-reactive protein(CRP) at Day 6

    Baseline and Day 6

  • Change from Baseline with ultrasound at Day 6

    Baseline and Day 6

Study Arms (2)

Ru-Yi-Jin-Huang-Saan

EXPERIMENTAL

Participants received Ru-Yi-Jin-Huang-Saan patch topically twice daily for 6 days.

Drug: Ru Yi Jin Huang Powder

Placebo

PLACEBO COMPARATOR

Participants received a starch patch topically twice daily for 6 days.

Drug: Placebo

Interventions

Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.

Also known as: golden patch
Ru-Yi-Jin-Huang-Saan

Each patch contains 13g starch and 10c.c. water.

Also known as: starch
Placebo

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • People who are over 20 years old and have no lack of mental ability can understand the content of the experiment and are willing to participate in it.
  • Patients with Colles' fracture receive surgical fixation(ORIF).

You may not qualify if:

  • People are unable to cooperate with experiments and fill out questionnaires.
  • Patients have wounds on the back of their wrists.
  • Patients are allergic to traditional Chinese medicine for external applications or have used other traditional Chinese medicine for external applications.
  • Patients have cancer, stroke, and systemic diseases such as severe anemia, thyroid disease, uncontrolled diabetes, etc.
  • Pregnant woman.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changhua Christian Hospital

Changhua, Changhua, 50006, Taiwan

RECRUITING

Related Publications (9)

  • Siu WS, Shiu HT, Shum WT, Ko Chun H, Lau CBS, Hung Leung K, Leung Ping C. Chinese topical herbal medicine gives additive effect on pharmaceutical agent on fracture healing. J Tradit Chin Med. 2019 Dec;39(6):853-860.

    PMID: 32186156BACKGROUND
  • Peng LH, Ko CH, Siu SW, Koon CM, Yue GL, Cheng WH, Lau TW, Han QB, Ng KM, Fung KP, Lau CB, Leung PC. In vitro & in vivo assessment of a herbal formula used topically for bone fracture treatment. J Ethnopharmacol. 2010 Sep 15;131(2):282-9. doi: 10.1016/j.jep.2010.06.039. Epub 2010 Jun 30.

    PMID: 20600749BACKGROUND
  • Raittio L, Launonen AP, Hevonkorpi T, Luokkala T, Kukkonen J, Reito A, Laitinen MK, Mattila VM. Two casting methods compared in patients with Colles' fracture: A pragmatic, randomized controlled trial. PLoS One. 2020 May 29;15(5):e0232153. doi: 10.1371/journal.pone.0232153. eCollection 2020.

    PMID: 32469881BACKGROUND
  • Wah JW, Wang MK, Ping CL. Construct validity of the Chinese version of the Patient-rated Wrist Evaluation Questionnaire (PRWE-Hong Kong Version). J Hand Ther. 2006 Jan-Mar;19(1):18-26, quiz 27. doi: 10.1197/j.jht.2005.10.003.

    PMID: 16473730BACKGROUND
  • Neumaier M, Braun KF, Sandmann G, Siebenlist S. C-Reactive Protein in Orthopaedic Surgery. Acta Chir Orthop Traumatol Cech. 2015;82(5):327-31.

    PMID: 26516948BACKGROUND
  • Sebastin SJ, Chung KC. An Asian perspective on the management of distal radius fractures. Hand Clin. 2012 May;28(2):151-6. doi: 10.1016/j.hcl.2012.03.007.

    PMID: 22554658BACKGROUND
  • Yang NP, Chan CL, Yu IL, Lee CY, Chou P. Estimated prevalence of orthopaedic fractures in Taiwan--A cross-sectional study based on nationwide insurance data. Injury. 2010 Dec;41(12):1266-72. doi: 10.1016/j.injury.2010.05.025. Epub 2010 Jun 17.

    PMID: 21288468BACKGROUND
  • Raudasoja L, Aspinen S, Vastamaki H, Ryhanen J, Hulkkonen S. Epidemiology and Treatment of Distal Radius Fractures in Finland-A Nationwide Register Study. J Clin Med. 2022 May 18;11(10):2851. doi: 10.3390/jcm11102851.

    PMID: 35628978BACKGROUND
  • Lin LC, Wang WH, Chang WK, Gao JL, Yang RC, Hsu PC, Lo LC. Evaluation of the Efficacy of the Traditional Chinese Medicine Formulation Ru-Yi-Jin-Huang-Saan on Colles Fracture After Surgery: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Res Protoc. 2025 Mar 5;14:e56849. doi: 10.2196/56849.

MeSH Terms

Conditions

Colles' Fracture

Interventions

Starch

Condition Hierarchy (Ancestors)

Fracture DislocationJoint DislocationsJoint DiseasesMusculoskeletal DiseasesWounds and InjuriesRadius FracturesFractures, Bone

Intervention Hierarchy (Ancestors)

GlucansBiopolymersPolymersMacromolecular SubstancesDietary CarbohydratesCarbohydratesPolysaccharides

Study Officials

  • LienCheng Lin, Master

    Changhua Christian Hospital

    STUDY CHAIR

Central Study Contacts

LienCheng Lin, Master

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director of Department of Traditional Chinese Medicine

Study Record Dates

First Submitted

November 26, 2022

First Posted

December 6, 2022

Study Start

May 1, 2023

Primary Completion

June 30, 2025

Study Completion

September 30, 2025

Last Updated

March 19, 2025

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations